VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced that the Biologics License Application for Lonapegsomatropin was accepted by the China National Medical Products Administration.

Scroll to Top